Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 5, 2025Open Access

Supplementary Figure 3 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited

View Full Paper
Ask AI
Bookmark
Share

Authors

LRLuis Gerardo Rodríguez‐LobatoOCOriol CardúsJMJoan Mañé-Pujol

Discussion

Loading...

Member takes

Overview

CAR T-cell proliferation shows effectiveness against myeloma in K562 cell lines despite limited BCMA expression.

Key Points

  • Bicistronic CAR T-cells control myeloma cells even with limited BCMA expression, demonstrating effectiveness against this cancer.
  • Proliferation of CAR T-cells was notably observed when co-cultured with K562 cell lines expressing CD229 antigen.
  • The effectiveness of CAR T-cells against myeloma was gauged over a 72-hour co-culture period with K562 cell lines.
  • These findings suggest that targeting both BCMA and CD229 may enhance treatment options for myeloma patients.

Cite This Study

Rodríguez‐Lobato et al. (2025) studied this question.

synapsesocial.com/papers/68c23a2cb210217d6477fbcchttps://doi.org/10.1158/2326-6066.30029632
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Supplementary Figure 4 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited2025
  2. 2Supplementary Figure 5 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited2025
  3. 3Supplementary Figure 1 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited2025
  4. 4Supplementary Figure 2 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited2025
  5. 5Supplementary Figure 6 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited2025